April 10, 2017
A swing and a miss
Ever since the EMPA-REG data became public everyone assumed that Jardiance from Lilly (NYSE: LLY) would take the lead in the expanding SGLT-2 market. That given the ground-breaking results this drug would overtake Invokana from Johnson and Johnson (NYSE: JNJ) and Farxiga from AstraZeneca (NYSE: AZN), two competing SGLT-2’s who did not have any hard-cardiovascular data. It was also thought that this is data would adversely impact Januvia, the leading DPP4 from Merck (NYSE: MRK . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
